Bristol-Myers Squibb Company BMY
NYSE · United States · Health Technology
$62.40-0.46 (-0.73%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
PRINCETON, N.J., September 30, 2026--U.S. FDA Approves Expanded Indication for BMS’s CAMZYOS for the Treatment of Symptomatic oHCM in Adults and Pediatric Patients
Investors seeking a high yield and stable fundamentals in the healthcare sector need look no further than Bristol Myers Squibb.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
A spokesperson confirmed that a “limited number” of liver-related safety events, including a patient death, were observed in testing of Bristol Myers’ admilparant — though it’s unclear whether the drug was to blame.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.